title: Tumor cell transformation using antisense oligonucleotide.
abstract: Major histocompatibility complex (MHC) Class II-positive, invariant chain (Ii)-suppressed tumor cells induce both T helper and cytotoxic T lymphocytes' responses. Genetically controlled immunotherapy could be utilized for prophylactic vaccination of tumor-free individuals who are at high risk of developing tumor and can be therapeutic for treating established tumors that are nonresponsive to existing therapies. In this chapter, we provide practical methods to create a potent in vivo tumor cell vaccine by inducing MHC Class II and Ii using MHC Class II transactivator (CIITA) or interferon-gamma (IFN-γ) and subsequently inhibiting Ii by antisense oligonucleotides. We also describe the development of an adenoviral vector.
authors.affiliation: College of Pharmacy, University of Louisiana at Monroe, Monroe, LA, USA.
authors.forename: Mohamed R
authors.initials: MR
authors.lastname: Akl
authors.forename: Nehad M
authors.initials: NM
authors.lastname: Ayoub
mesh_terms: D000256:Adenoviridae / Q000235:genetics; D000818:Animals; D019496:Cancer Vaccines / Q000235:genetics* / Q000276:immunology*; D045744:Cell Line, Tumor; D002471:Cell Transformation, Neoplastic / Q000235:genetics*; D004274:DNA, Recombinant / Q000235:genetics; D018274:Electroporation; D004789:Enzyme Activation; D005822:Genetic Vectors / Q000235:genetics; D006681:HLA-D Antigens / Q000235:genetics; D006801:Humans; D007371:Interferon-gamma / Q000235:genetics; D051379:Mice; D009687:Nuclear Proteins / Q000235:genetics; D016376:Oligonucleotides, Antisense / Q000235:genetics*; D016914:Ribonuclease H / Q000378:metabolism; D015534:Trans-Activators / Q000235:genetics; D014162:Transfection; D014611:Vaccination
chemical_list: D019496:Cancer Vaccines; D004274:DNA, Recombinant; D006681:HLA-D Antigens; C083728:MHC class II transactivator protein; D009687:Nuclear Proteins; D016376:Oligonucleotides, Antisense; D015534:Trans-Activators; D007371:Interferon-gamma; D016914:Ribonuclease H